'Tip of the iceberg': Novartis-partnered UC Berkeley lab churns out a startup to tackle protein stabilization

Kyle LaHucik

Senior Reporter

For the past decade, Daniel Nomura’s lab at UC Berkeley has been working to find chemical approaches to drug the so-called “undruggable,” and with the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Tip of the iceberg': Novartis-partnered UC Berkeley lab churns out a startup to tackle protein stabilization

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

'Tip of the ice­berg': No­var­tis-part­nered UC Berke­ley lab churns out a start­up to tack­le pro­tein sta­bi­liza­tion

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

'Tip of the iceberg': Novartis-partnered UC Berkeley lab churns out a startup to tackle protein stabilization